Explore Log in Sign up

Explore

@midgardfinance.com Oct 1, 2026, 3:30 PM

💉 #pharma #EASD2026

🇺🇸 $LLY #eloralintide added 8.5 points of weight loss to tirzepatide in type 2 diabetes: 23.3% vs 14.8%, 48 wk.

🇩🇰 $NOVO #CagriSema: 4.0 added to semaglutide, 14.2% vs 10.2%, 68 wk. One-molecule #zenagamtide: 14.6%, 36 wk.

Separate trials.

midgardfinance.com/diabetes/

Chart titled "Amylin added 8.5 points to tirzepatide, 4.0 to semaglutide". Three rows, each a separate trial in adults with type 2 diabetes, showing the average weight loss at the top dose as estimated for people staying on treatment. Top row, Lilly, two molecules, phase 2b, 48 weeks: a grey point for tirzepatide 15 mg alone at 14.8 per cent joined to a red point for the same dose with eloralintide 9 mg at 23.3 per cent. Middle row, Novo, two molecules, the REIMAGINE 2 trial, phase 3, 68 weeks: a grey point for semaglutide 2.4 mg alone at 10.2 per cent joined to a blue point for the same dose with cagrilintide 2.4 mg at 14.2 per cent. Bottom row, Novo, one molecule, phase 2, 36 weeks: a single blue point for zenagamtide 40 mg at 14.6 per cent, marked as having no arm without amylin, because both actions are in the same molecule. The rows are not a ranking: the trials differ in length, stage and participants, and only the gap inside a row compares like with like.

Terms of Use Privacy Policy Community Standards Help Get the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-10 01:38:52 EDT